Objective To evaluate the effect of endovascular stenting combined with external constriction valvuloplasty of superficial femoral vein for the treatment of Cockett syndrome. MethodsForty two cases of Cockett syndrome with femoral veins reflux were treated with iliac vein stent implantation or venoplasty, and superficial femoral veins were constricted with ePTFE graft patch at the level of the first valves. ResultsThe iliac veins were all patent after stent implantation. A follow up of 8 to 45 months revealed that limb swelling disappeared in 38 cases with no varicose. Slight limb swelling was left over in 3 cases. Stent thrombosis developing in one case two months later subsided after a successful thrombolysis. ConclusionThe procedure is mini invasive, safe and effective for the treatment of Cockett syndrome.

Objective To evaluate the role of temporary arteriovenous fistula(AVF) in the treatment of acute deep venous thrombosis(DVT) with Amplatz thrombectomy device(ATD). Method Seventy-six cases of acute DVT underwent mechanical thrombolysis with ATD, in which 50 cases received a temporary AVF after interventional therapy. Result One case died of pulmonary embolism. Ipsilateral limbs swelling subsided and pain alleviated in the remaining 72 cases since first post-operative day. Secondary contralateral DVT developed in 2 cases on the 7th post-operative day. The patency of temporary AVF was 86%(43/50). Sixty-eight cases (90.7%) were followed-up for 10~42 months post-operatively with limbs swelling completely subsided in 59 cases and ameliorated in 6 cases. Secondary inferior vena cava thrombosis developed in one case and 2 cases died of unrelated diseases. Conclusion Temporary AVF increases blood flow volume and blood velocity in the thrombectomized vein segment to improve the vein patency, hence is a valuable auxiliary means of ATD.

Objective To explore the appropriate method for mechanical thrombectomy, selection of vena cava filter and its duration in place. Method Fifty-five cases of severe acute deep vein thrombosis of the lower limbs were enrolled. Vena cava filter was first placed, then thrombectomy was performed with Amplatz thrombectomy device (ATD). The iliac vein lesions were dilated by balloon followed by temporary arterivenous fistula construction. Result Procedures were all successful in 52 cases, iliac vein stenosis was found in 47 cases and dilated by balloon. Permanent vena cava filters were placed in 20 cases while temporary in 32 cases. Fifty cases were followed-up for 3～30 monthes. Tumefaction disappeared in 46 cases leaving no after thrombosis syndrome. Conclusion This comprehensive modality is effective, less traumatic and of quick recovery. During the procedure, possible residual thrombi should always be under close attention and stenosis in iliac veins be confirmed by repeated venography. In most cases, placing a temporary vena cava filter was the best choice.

ObjectiveForskolin （FSK） analogs，isoforskolin （isoF），deacetylforskolin（deaF），and 1-acetylforskolin（1-aF），extracted from Coleus forskohlii native to Yunnan，were assayed for their adenylate cyclase stimulating activities in vitro and for effects of two analogs on ocular hypertension （OHT） in water-loaded rabbits．MethodsAdenylate cyclase stimulation was determined by protein-binding method of radioimmunoassay，and intraocular pressure was monitored by pneumatonometer．ResultsIt showed that isoforskolin and forskolin stimulated adenylate cyclase in vitro with almost equal activity，deacetylforskolin with milder activity，and 1-acetylforskolin with little activity in vitro．1％ deaF and 1-aF suppressed rabbit OHT induced by water-loading for at least 3h，with the maximal inhibitory rates of 6.0，10.9% respectively．ConclusionThis study suggests that two foskolin analogs （isoforskolin，deacetylforskolin） possess adenylate cyclase stimulation activities in vitro；deacetylforskolin and 1-acetylforskolin suppress OHT induced by water-loading in rabbits．

To investigate effects of l% l-acetylforskoin (l-aF) suspension eye-drops administeredtopically on intraocular pressure (IOP) in rabbits and men, and observe the loca l irritation of the drug． l% l-aF suspension eye-drops was prepared and was instilled into one of e yes while the corresponding vehicle into the contralateral eye as control． IOP was measured b y pneumatonometer before and after administration． l%1-aF suspension eye-drops s ig nificantly reduced IOP in rabbits reaching the maximum reduction of 2.2 mmHg and lasting a t least 3 hours． But it didnt show significant effects in men． There was little local irritati on neither in rabbits nor in men． l% l-aF suspension eye-drops significantly reduced IOP in normal rabbit s, but not in men． No local irritation was observed in rabbits and in men．

Objective To evaluate the effects of Amplatz thrombectomy device (ATD), thrombolysis (TL), and surgical thrombectomy (TX) on venous wall morphology complicated with acute femoral vein thrombosis in dogs. Methods The femoral venous thrombosis model was induced in 36 adult mongrel dogs. The thrombosed veins were treated with ATD ( n =12), TL ( n =12), and TX ( n =12), respectively. Results Clearance of thrombus was successful in all cases. One week after treatment, the rate of venous patency in ATD, TL, and TX group was 75%, 33%, and 25%, respectively ( P

Objective To compare the clinical efficacy and safety of pegylated interferon α-2a (Peg IFN α-2a) or adefovir dipivoxil(ADV) monotherapy and their combination therapy in HBeAg positive chronic hepatitis B (CHB) patients. Methods An open randomized controlled multicenter clinical trial was performed. One hundred and twenty cases with CHB were divided into 3 groups: Peg IFN α-2a monotherapy (group A), ADV monotherapy (group B) and Peg IFN α-2a plus ADV combination therapy (group C). The virological response (VR), serological response (HBeAg, HBsAg clearance and seroconversion), biochemical response (BR) and sustained response (SR) were tested at week 24 and 48 of therapy and week 48 of follow-up after end of treatment (EOT) for'evaluation of therapeutic effects, safety and drug resistance. The efficacy was compared using X2 test. Results At week 48 of treatment, the VR (HBV DNA ≤500 copy/mL) rates were 36. 8%(14/38), 37. 5%(15/40) and 62. 9% (22/35), respectively in groups A, B and C; that in group C was higher than those in groups A and B (X2 = 4. 933, 4. 801, respectively; both P < 0. 05); HBeAg seroconversion rates in three groups were 44. 7% (17/38), 17. 5% (7/40) and 51. 4% (18/35), respectively. At week 48 of follow-up,SR rates in three groups were 34. 2%(13/38), 15. 0%(6/40) and 48. 6% (17/35), respectively; those in groups C and A were higher than that in group B (X2 = 9. 894,P<0. 01;X2 =3. 903, P<0. 05, respectively). Conclusions VRs at week 24 and 48 of Peg IFN α-2a plus ADV combination therapy are better than Peg IFN α-2a or ADV monotherapy. SRs at week 48 of follow-up after Peg IFN α-2a monotherapy and combination therapy are both better than ADV monotherapy.

Objective: To investigate the expression of CD160 in HIV-specific T cells and their subsets in peripheral blood of asymptomatic human immunodeficiency virus (HIV) infected individuals. Methods: A total of 43 asymptomatic HIV-infected individuals without antiretroviral therapy (ART) and 18 healthy controls were recruited from the No. 302 Hospital of PLA between June 2014 and November 2015. Peripheral blood mononuclear cells (PBMC) were isolated from peripheral bloods of these subjects. CD160 was stained with fluorescent antibody. Expression of CD160 in HIV-specific T cells and their subsets was detected by flow cytometry. Results: The frequency and median fluorescence intensity (MFI) of CD160 on the whole HIV-specific CD4+ T cells and CD8+ T cells were higher than those in the healthy controls(P<0.01). In subsets of HIV-specific CD4+ T cells, the MFI of CD160 in CD4+ Tn cells and CD4+ Teff cells, and the frequency of CD160 in CD4+ Teff cells were significantly increased (P<0.01). CD8+ Tn fine, CD8+ Tcm cells and CD8+ Tem cells showed a significant upregulation in the frequency and MFI of CD160 (P<0.01). Conclusions Chronic HIV infection can lead to high expression of CD160 in HIV-specific T cells and their different subsets, causing cellular immune dysfunction, which may further impair the ability to control the HIV virus.